Patents by Inventor Mónica Sarria Núnez

Mónica Sarria Núnez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta hairpin peptides having antiviral properties against Dengue virus
    Patent number: 9896482
    Abstract: The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: February 20, 2018
    Assignee: Centro de Ingenieria Genética y Biotechnologia
    Inventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martín Dunn, Hilda Elisa Garay Pérez, Osvaldo Reyes Acosta, Viviana Falcón Cama, Dianne Pupo Gómez, Alexis Yero Díaz, Gabriel Jesús Márquez Perera, Mónica Sarría Núñez, Osmany Guirola Cruz, Rocío Garateix Suárez, Karen Alvarez Pérez, Sonia González Blanco, Mariela Vázquez Castillo, Luis Javier González López
  • BETA HAIRPIN PEPTIDES HAVING ANTIVIRAL PROPERTIES AGAINST DENGUE VIRUS
    Publication number: 20170152290
    Abstract: The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.
    Type: Application
    Filed: February 26, 2015
    Publication date: June 1, 2017
    Inventors: Glay CHINEA SANTIAGO, Vivian HUERTA GALINDO, Alejandro Miguel MARTÍN DUNN, Hilda Elisa GARAY PÉREZ, Osvaldo REYES ACOSTA, Viviana FALCÓN CAMA, Dianne PUPO GÓMEZ, Alexis YERO DÍAZ, Gabriel Jesús MÁRQUEZ PERERA, Mónica SARRÍA NÚÑEZ, Osmany GUIROLA CRUZ, Rocío GARATEIX SUÁREZ, Karen ALVAREZ PÉREZ, Sonia GONZÁLEZ BLANCO, Mariela VÁZQUEZ CASTILLO, Luis Javier GONZÁLEZ LÓPEZ
  • Chimerical peptidic molecules with antiviral properties against the viruses of the Flaviviridae family
    Patent number: 8674063
    Abstract: The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: March 18, 2014
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martin Dunn, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Mónica Sarría Núñez, Alexis Musacchio Lasa, Olvaldo Reyes Acosta, Hilda Elisa Garay Pérez, Anìa Cabrales Rico
  • Method to block the infection by flaviviruses, molecules and uses
    Patent number: 8420311
    Abstract: The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: April 16, 2013
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Vivian Huerta Galindo, Glay Chinea Santiago, Noralvis Fleitas Salazar, Alejandro Miguel Martin Dunn, Monica Sarria Nunez, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Aniel Sanchez Puente, Vladimir Armando Besada Perez, Osvaldo Reyes Acosta, Hilda Elisa Garay Perez, Ania Cabrales Rico, Alexis Musacchio Lasa, Gabriel Ramon Padron Palomares, Luis Javier Gonzalez Lopez
  • METHOD TO BLOCK THE INFECTION BY FLAVIVIRUSES, MOLECULES AND USES
    Publication number: 20110212105
    Abstract: The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.
    Type: Application
    Filed: April 26, 2007
    Publication date: September 1, 2011
    Inventors: Vivian Huerta Galindo, Glay Chinea Santiago, Noralvis Fleitas Salazar, Alejandro Miguel Martín Dunn, Mónica Sarría Núñez, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Aniel Sánchez Puente, Vladimir Armando Besada Pérez, Osvaldo Reyes Acosta, Hilda Elisa Garay Pérez, Ania Cabrales Rico, Alexis Musacchio Lasa, Gabriel Ramón Padrón Palomares, Luis Javier González López
  • Methods and Proteins for the Prophylactic and/or Therapeutic Treatment of Four Serotypes of Dengue Virus and Other Flaviviruses
    Publication number: 20090312190
    Abstract: The present invention is related to the field of the pharmaceutical industry, and describes a conserved area on the surface of the E protein that can be used for the development of wide-spectrum antiviral molecules to be employed in the prophylaxis and/or treatment of infections due to Dengue Virus serotypes 1-4 and other flaviviruses. The invention also covers chimeric proteins to be used as vaccines or as a prophylactic or therapeutic treatment against the four serotypes of Dengue Virus and other flaviviruses.
    Type: Application
    Filed: November 21, 2006
    Publication date: December 17, 2009
    Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA
    Inventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martin Dunn, Jorge Victor Gavilondo Cowley, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Jeovanis Gil Valdés, Aída Zulueta Morales, Lisset Hermida Cruz, Marta Ayala Avila, Diamilé Gonzáles Roche, Rolando Paez Meireles, Patricia Gabriela Toledo Mayora, Mónica Sarria Núnez, Alexis Musacchio Lasa, Yuliet Mazola Reyes